Back to search results

Study of MK-8527 and Methadone in Healthy Volunteers

This study is looking at how a medicine called MK-8527 affects levels of methadone in the body. Researchers want to understand what happens to methadone in healthy people after they take MK-8527. The study will measure the amount of methadone in your blood for up to 24 hours after taking the medicines. You might be able to join if you are a healthy adult between 18 and 65 years old with a body mass index (BMI) between 18 and 35. People with certain health conditions, like heart or kidney problems, cannot participate. The study aims to enroll 14 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 14 healthy participants. It will investigate the effect of MK-8527 on methadone levels.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements will be taken for up to 24 hours after dosing.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07528508

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

Completed
PHASE1Ages 18–65InterventionalBasic science
Merck Sharp & Dohme LLC
~14 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:MK-8527Methadone

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone
Measured over Up to 24 hours
+1 more outcome measured

Conditions

Healthy

Explore related trials

Healthy Volunteers

NCT07528508

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Pinnacle Research Group ( Site 0002)

    Anniston, Alabamano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharpe & Dohme LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has a body-mass index (BMI) between 18 and 35 kg/m\^2

Exclusion

Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Has a history of cancer (malignancy)
Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food
Has a positive test(s) for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)

What this trial measures

  • Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-MethadoneUp to 24 hours

    The dose-normalized AUC0-24hr of R-methadone will be determined on Day 1.

  • Dose-Normalized AUC0-24 of S-MethadoneUp to 24 hours

    The dose-normalized AUC0-24hr of S-methadone will be determined on Day 1.